DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 07/17/2017-07/21/2017 404 BNA Dr., Bldg. 200, Ste. 500 FEI NUMBER Nashville, TN 37217-2597 (615) 366-7801 Fax: (615) 366-7802 3013497126 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Matthew L. McDonald, Owner Triad Rx, Inc. 26258 Pollard Road CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Daphne, AL 36526 Producer of Sterile and Non-sterile Drugs

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

OBSERVATION 1

Cleaning pads or wipes used in the ISO 5 area are not sterile.

Specifically, the (b) (4) wipers used to clean the ISO 5 area are not sterile.

OBSERVATION 2

The ISO-classified areas have difficult to clean, particle-generating, or visibly dirty equipment or surfaces.

Specifically, a lyophilizer and a portable dehumidifier are located in the clean room (ISO 7) adjacent to the ISO 5 area.

OBSERVATION 3

Inadequately or un-protected product intended to be sterile was observed to be exposed to lower than ISO 5 quality air.

Specifically, drug products intended to be lyophilized are (b) (4) in the ISO 5 area, partially stoppered, and then transferred to the lyophilizer (ISO 7 area) via unprotected/uncovered trays.

OBSERVATION 4

Personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves.

Specifically, on 07/17/2017, I observed clean room operator, with initials (b) (6) perform aseptic processing in the ISO 5 area. The operator did not always disinfect or change gloves before reentering the ISO 5 area after retrieving materials or discarding waste in the ISO 7 area. The following lots were produced without adequate glove disinfection/changes:

-Sermorelin Acetate 9mg/GHRP-2 9mg Lyophilized, lot 07172017@25

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	EMPLOYEE(9) NAME AND TITLE (Print or Type) Brandon C. Heltmeler, Investigator	07/21/2017
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	Page 1 OF 2

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 07/17/2017-07/21/2017 404 BNA Dr., Bldg. 200, Ste. 500 FEI NUMBER Nashville, TN 37217-2597 (615)366-7801 Fax: (615)366-7802 3013497126 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Matthew L. McDonald, Owner STREET ADDRESS Triad Rx, Inc. 26258 Pollard Road CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Daphne, AL 36526 Producer of Sterile and Non-sterile Drugs

-Sermorelin Acetate 3mg/GHRP-6 3mg, Lyophilized, lot 07172017@24

OBSERVATION 5

Personnel engaged in aseptic processing were observed with exposed hands, wrists, legs, hair, or mouth.

Specifically, on 07/17/2017, I observed clean room operator, with initials (b) (6) enter the ISO 5 area with bare hands then put on sterile gloves and proceed with aseptic processing. The following lots were produced:

- -Sermorelin Acetate 9mg/GHRP-2 9mg Lyophilized, lot 07172017@25
- -Sermorelin Acetate 3mg/GHRP-6 3mg, Lyophilized, lot 07172017@24

OBSERVATION 6

Equipment, materials, and/or supplies are not disinfected prior to entering the aseptic processing areas.

Specifically, on 07/17/2017, I observed clean room operator, with initials (b) (6) move a (b) (4) from the ISO 7 area to the ISO 5 area without first disinfecting the equipment.

OBSERVATION 7

Personnel were observed conducting aseptic manipulations or placing equipment/supplies in an area that blocked the movement of first pass air around an open unit, whether before or after it is filled with sterile product.

Specifically, on 07/17/2017, I observed clean room operator, with initials (b) (6) place hands and arms over open glass vials during aseptic filling of the following products:

- -Sermorelin Acetate 9mg/GHRP-2 9mg Lyophilized, lot 07172017@25
- -Sermorelin Acetate 3mg/GHRP-6 3mg, Lyophilized, lot 07172017@24

OBSERVATION 8

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	Page 2 OF 2
OF THIS PAGE	19CK		07/21/2017
SEE	EMPLOYEE(S) SIGNATURE	EMPLOYEE(8) NAME AND TITLE (Print or Type) Brandon C. Hellmeler, Investigator	DATE ISSUED

		NT OF HEALTH AND HUM			
404 BNA Dr., F Nashville, TN	FOOD AND DRUG ADN STRICT ADDRESS AND PHONE NUMBER 04 BNA Dr., Bldg. 200, Ste. 500 ashville, TN 37217-2597		DATE(S) OF INSPECTION 07/17/2017-07/21/2017 FEI NUMBER		
(615) 366-7801 Fax: (615) 366-7802			3013497126		
Matthew L. McDo					
FIRM NAME		STREET ADDRE	777 51 10 20 20 20 20 20 20 20 20 20 20 20 20 20		
Triad Rx, Inc.	v		ard Road		
Daphne, AL 36526				terile and Non-sterile Drugs	
OBSERVATION 9 The use of sporic Specifically, your (b) (4) mix	idal agents in the cleanroo r firm uses a prepared blea ed with (b) (4) time for this concentration	oms and/or ISO 5	that consists of (b) (4) (However, your firm ha	of (b) (4) as not established as	
SEE REVERSE OF THIS PAGE	PLOYEE(S) SIGNATURE		NAME AND TITLE (Print or Type) meler, Investigator	DATE ISSUED 97/21/2017	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL	OBSERVATIONS	Page 3 OF 2	